Эффективность и безопасность пиоглитазона (Актос?) в качестве монотерапии и в комбинации с глибенкламидом или метформином у пациентов с сахарным диабетом типа 2
Аннотация
Об авторах
Марина Владимировна ШестаковаМихаил Иванович Балаболкин
Михаил Борисович Анциферов
Александр Юрьевич Майоров
Л А Чугунова
Минара Шамхаловна Шамхалова
Н Н Бревнова
И В Науменкова
Наталья Владиславовна Зайцева
Л В Цибина
Иван Иванович Дедов
Список литературы
1. Балаболкин М.И., Клебанова Е.М., Майоров А.Ю., Анциферов М.Б. Этиология и патогенез сахарного диабета 2 типа.// В руководстве для врачей «Сахарный диабет» (И.И. Дедов, М.В. Шестакова), Универсум Паблишинг, Москва, 2003, с. 1 33-150.
2. Майоров А.Ю., Науменкова И.В. Современные сахароснижающие средства в лечении сахарного диабета 2 типа.// Русский медицинский журнал, 2001, т. 9, №24, с. 1 105-11 11.
3. Belcher G, Michel J . Tolerability profile of PIO in combination with SU or MET in controlled clinical trials.// Diabetes, 2001, v. 50, suppl. 2, p. A416.
4. Bonora E, Formentini G, Calcaterra F, Marini F, Muggeo M. Homeostasis model assessment of insulin resistance predicts cardiovascular disease in type 2 diabetes mellitus.// Diabetes 49, 2000, suppl. 1: A21.
5. Brockley MR, Schneider RL. The onset of blood glucose response in patients with Type 2 diabetes treated with pioglitazone.// Diabetes, 2000, v. 49, suppl. l,p. A99.
6. Definition, diagnosis and classification of diabetes mellitus and its complications.// Report of WHO Consultation, 1999.
7. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerosis cardiovascular disease.// Diabetes Care, 1991, v. 14, p. 173-194.
8. Einhorn D, Kipnes M, Glazer NB, Wishner W, and the Pioglitazone 031 Study Group. Durability of glycemic control with pioglitazone in long-term combination and monotherapy.// Diabetes, 2001, v.50, suppl. 2, p. A l 11.
9. Einhorn D, Rendell M, Rosenzweig J Egan JW6 Mathisen AL6 Schneider RL for the Pioglitazone 027 Study Group. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. / / Clin Ther, 2000, v. 22, p. 1395-1409.
10. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin resistance syndrome (SyndromeX).// Diabetes, 1992, v. 41, p.715-722.
11. Kipnes M, Boss A. Glycemic control in Type 2 diabetes is improved by long-term pioglitazone/sulfonylurea combination therapy.// Diabetologia, 2001, v. 44, suppl. 1, p. A233.
12. Lean ME, Priest M, Stump S, Martin M, Slater C, Gibson C, Edwards G. Pioglitazone reduces intra-abdominal fat.// Diabetologia, 2001, v. 44, suppl. 1, p. A220.
13. Martens FMAC, Visseren FU, Lemay J , de Koning EJP, RabelinkTJ. Metabolic and additional vascular effects of thiazolidinediones.// Drugs, 2002, v.62, p. 1463-1480.
14. Martin ВС, Warram JH, Krolewski AS, Bergman RN, Soelbner JS, Kahn CR. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of 25 year follow-up study.// Lancet, 1992, v. 340, p. 925-929. атура
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and _-cell function from fasting plasma glucose and insulin concentrations in man.// Diabetologia, 1985, v. 28, p. 412-419.
16. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino U, DeFronzo RA. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.// Diabetes Care, 2001, v. 24, p. 710-719.
17. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J , Cusi K, Mandarino U, DeFronzo RA. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.// J Clin Endocrinol Metab, 2002, v. 87, p. 2784-2791.
18. Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes.// Diabetes Care, 2002, v. 25, p. 517-523.
19. Mudaliar S, Henry RR. PPAR agonists in health and disease: a pathophysiologic and clinical overview.// Curr Opin Endocrinol Diabetes, 2002, v. 9, p. 285-302.
20. Reaven GM. Insulin resistance and its consequences: non-insulin dependent diabetes mellitus and coronary heart disease.// In: LeRoith D, Taylor SE, Olefsky J M , eds. Diabetes mellitus. Philadelphia: Lippincott-Raven, 1996, p. 509-519.
21. Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.// Coron Artery Dis, 2001, v. 12, p. 413-423.
22. Rosenstock J for the Pioglitazone HCI Study Group. Improved insulin sensitivity and beta cell responsivity suggested by HOMA analysis of pioglitazone therapy.// Diabetologia, 2000, v. 43, suppl. 1, p. A192.
23. Stratton IM, Adler Al, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovasclular and microvascluar complications of type 2 diabetes (UKPDS 35): prospective observational study.// BMJ, 2000, v. 321, p. 405-412.
24. Tobian J , Pinaire J , Zagar A, Zheng S, Glazer NB, Prince M, and the Pioglitazone 012 Study Group. Effects of pioglitazone on HDL-cholesterol levels are independent of changes in triglyceride.// Diabetologia, 2001, v. 44, suppl. l,p. A37.
25. Hannele Yki-Jarvine. Thiazolidinediones.//The N Engl J Med 2004; 351:1 106-18
Рецензия
Для цитирования:
Шестакова М.В., Балаболкин М.И., Анциферов М.Б., Майоров А.Ю., Чугунова Л.А., Шамхалова М.Ш., Бревнова Н.Н., Науменкова И.В., Зайцева Н.В., Цибина Л.В., Дедов И.И. Эффективность и безопасность пиоглитазона (Актос?) в качестве монотерапии и в комбинации с глибенкламидом или метформином у пациентов с сахарным диабетом типа 2. Сахарный диабет. 2005;8(1):50-57.
For citation:
Shestakova M.V., Balabolkin M.I., Antsiferov M.B., Mayorov A.Yu., Chugunova L.A., Shamkhalova M.Sh., Brevnova N.N., Naumenkova I.V., Zaytseva N.V., Tsibina L.V., Dedov I.I. Effektivnost' i bezopasnost' pioglitazona (Aktos?) v kachestve monoterapii i v kombinatsii s glibenklamidom ili metforminom u patsientov s sakharnym diabetom tipa 2. Diabetes mellitus. 2005;8(1):50-57. (In Russ.)